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Abstract
Background: Non-high density lipoprotein cholesterol (HDL-C) could be a good predictor of vascular disease
outcomes. To evaluate the association between serum non-HDL-C and cognitive impairment in patients with acute
ischemic stroke.
Methods: A total of 725 hospitalized patients with acute ischemic stroke were enrolled. They received conventional
treatment. Cognitive function was assessed on the 3rd day after admission using mini-mental state examination
(MMSE), Montreal Cognitive Assessment (MoCA), Activity of Daily Living Scale (ADL), and Neuropsychiatric Inventory
(NPI, and Hamilton depression rating scale 21-item (HAMD-21). Lipid profile and biochemical markers were
measured, and non-HDL-C was calculated.
Results: Compared with patients with normal non-HDL-C, those with high non-HDL-C showed lower MMSE
(23.1 ± 4.9 vs. 26.0 ± 4.6, P < 0.001) and MoCA (20.4 ± 6.4 vs. 22.2 ± 5.3 P = 0.01) scores, higher NPI (6.2 ± 1.2 vs.
3.3 ± 1.5, P < 0.001) and HADM-21 (6.0 ± 2.2 vs. 4.5 ± 1.9, P < 0.001) scores, and higher homocysteine (16.0 ± 3.8
vs. 14.3 ± 2.0 mmol/L, P = 0.044), fasting blood glucose (6.4 ± 2.7 vs. 6.1 ± 2.1 mmol/L, P = 0.041), and HbA1c
(6.80 ± 1.32 % vs. 6.52 ± 1.17 %, P = 0.013) levels. MMSE (r = -0.526, P < 0.001), MoCA (r = −0.216, P < 0.001), and
NPI (r = 0.403, P < 0.001) scores were correlated with non-HDL-C levels. High non-HDL-C levels were an
independent risk factor for cognitive disorders after acute ischemic stroke (P = 0.034, odds ratio = 3.115, 95 %
confidence interval: 1.088–8.917).
Conclusions: High serum non-HDL-C levels, age, education, homocysteine levels, and HAMD score were
independent risk factors of cognitive impairment in patients with acute ischemic stroke. The risk of cognitive
disorders after acute ischemic stroke increased with increasing non-HDL-C levels. This parameter is easy to
assess in the clinical setting.
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Background
Acute ischemic stroke is an episode of neurological dys-
function caused by cerebral ischemia persisting for >24 h
or until death [1], and represent 80–87 % of all
strokes [2, 3]. In high income countries, the incidence
of stroke is 217 per 100,000 person-years and the
prevalence is 715 per 100,000 people, compared with
low income countries where the incidence is 281 per
100,000 person-years and the prevalence is 393 per
100,000 people. Likely risk factors include history of
transient ischemic attacks, cardiovascular diseases (hyper-
tension, myocardial infarction), smoking, metabolic syn-
drome, heavy alcohol consumption, type 2 diabetes
mellitus, high cholesterol levels, carotid artery stenosis,
genetic factors, and biochemical factors [2, 3].
Vascular cognitive impairment (VCI) is one of the most
common non-somatic manifestations in patients with acute
ischemic stroke [4]. Dyslipidemia is not only an independ-
ent and maybe the most important risk factor for ischemic
stroke, which tends to cause hidden, progressive, and som-
atic organic damage, but also affects the cognitive function
of patients with ischemic stroke through accelerating sys-
temic atherosclerosis, and it is believed to be a risk factor
inducing cognitive disorders, even dementia [5].
Previous guidelines for blood lipid treatment preferred
low-density lipoprotein cholesterol (LDL-C) as the pri-
mary target of lipid-lowering therapy [6]. However, some
recent studies and epidemiological investigations indi-
cated that serum non-high-density lipoprotein choles-
terol (HDL-C) levels were superior to LDL-C in terms of
predicting the risk of cardiovascular diseases. The
National lipid association recommendations for patient-
centered management of dyslipidemia issued by the
American National Lipid Association (NLA) in 2015
proposes that non-HDL-C is preferable to LDL-C as the
primary target of interventions [7], since non-HDL-C in-
cludes all lipoprotein particles other than the HDLs,
therefore including the triglyceride-rich lipoproteins
[chylomicrons, very-low-density lipoproteins (VLDL),
and their remnants], which are now known to partici-
pate in atherosclerosis [7]. Nevertheless, the exact rela-
tionship between non-HDL-C and cognitive impairment
after stroke is still poorly understood.
Therefore, this study aimed to investigate the associ-
ation between serum non-HDL-C levels and cognitive
function after stroke, as well as the value of non-HDL-C




This was a retrospective case-control study of patients
with acute ischemic stroke hospitalized and registered at
the Department of Neurology of the Tianjin Huanhu
Hospital between January 2010 and December 2015. The
study was approved by the ethical committee of the
Tianjin Huanhu Hospital. The need for individual con-
sent was waived by the committee because of the retro-
spective nature of the study.
Patients
Inclusion criteria were: 1) newly diagnosed with ischemic
stroke according to the China cerebral vascular disease
guidelines [8] based on computed tomography (CT) and/
or magnetic resonance imaging (MRI); 2) onset time
≤7 days; and 3) aged >18 years old. Exclusion criteria were:
1) disturbance of consciousness, severe aphasia, or hemi-
plegia, and unable to complete neuropsychological testing;
2) Alzheimer’s disease (AD), depression, dementia with
Lewy bodies (DLB), frontotemporal dementia (FTD), or
dementia caused by other diseases such as malignant
tumors, intracranial infection, neurodegenerative diseases,
craniocerebral trauma, etc.; 3) heart, lung, liver, kidney, or
endocrine system diseases, or connective tissue diseases,
blood disease, or malnutrition; 4) history of mental dis-
eases or behavior disorders; 5) history of ischemic stroke
with cognitive disorders based on the medical files or
inquiry to the family at admission; or 6) history of nootro-
pics or antipsychotic drugs within 4 weeks.
Data collection
Patients’ gender, age, height, body mass index (BMI),
level of education, family history of dementia, presence
of vascular risk factors such as hypertension, diabetes,
hyperlipidemia, heart diseases (atrial fibrillation, myocar-
dial infarction, angina pectoris, asystole, etc.), history of
stroke and/or transient ischemic attack (TIA), smoking
history, and drinking history were recorded in details at
admission.
Grouping
The patients were divided into three subgroups according
to the Oxfordshire Community Stroke Project (OCSP) clas-
sification [9]: 1) total/partial anterior circulation infarction
(TACI/PACI) group; 2) posterior circulation infarction
(POCI) group; and 3) lacunar circulation infarction (LACI)
group. TACI manifests as a triad, i.e. manifestations of
complete middle cerebral artery syndrome: 1) cerebral and
high nervous disorders (disturbance of consciousness,
aphasia, acalculia, spatial disorientation, etc.); 2) homonym-
ous hemianopia or conjugate eye deviation; and 3) motor
and/or sensory disturbance at three contralateral parts
(face, upper limbs, and lower limbs). PACI manifests as two
out of three manifestations. POCI manifests as various de-
grees of vertebro-basilar artery syndromes: 1) ipsilateral
cerebral palsy and contralateral sensory disorders; 2)
bilateral sensory and motor disorders; 3) collaborative
movement disorders of eyes and cerebellar dysfunction,
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which are unequal brain-stem and cerebellar infarctions
caused by obstruction of vertebro-basilar artery and
branches. LACI manifests as lacunar syndrome.
Biochemistry
Overnight fasting blood samples were routinely drawn.
Fasting blood glucose, total cholesterol (TC), triglycerides
(TG), HDL-C, and LDL-C were measured using an
ADVIA-2400 automatic biochemical analyzer (Siemens,
Erlangen, Germany) and the triglyceride test kit (GPO-
PAP, Shanghai Huachen, Shanghai, China). A BNP II pro-
tein analyzer (Siemens, Erlangen, Germany) was used to
test serum high-sensitivity CRP (hs-CRP) (C-reactive pro-
tein kit, Siemens Healthcare Diagnostics Products GmbH,
Erlangen, Germany), glycated hemoglobin (HbA1c) (HBIC
HbA1c kit, Siemens Healthcare Diagnostics Products
GmbH, Erlangen, Germany), and homocysteine (Hcy)
(Hcy kit, Siemens Healthcare Diagnostics Products
GmbH, Erlangen, Germany).
Non-HDL-C was calculated by subtracting HDL-C
levels from TC. Non-HDL-C levels were classified into
two grades according to the criteria recommended by the
Patient-centered management of dyslipidemia developed
by the NLA in 2015 [7]: normal group (non-HDL-C
<3.4 mmol/l) and high group (non-HDL-C ≥3.4 mmol/l).
The high group can be further divided into higher than
normal (3.4 mmol/l ≤ non-HDL-C <4.2 mmol/l), critical
high (4.2 mmol/l ≤ non-HDL-C <5.0 mmol/l), and very
high (non-HDL-C ≥5.0 mmol/l).
Neurological assessment
After admission, patients were routinely given anti-
platelet, anticoagulation, expansion, and other conven-
tional treatments for stroke [3]. On the 3rd day after
admission, their neuropsychological scales were rou-
tinely assessed by trained and skilled neurologists. Cog-
nitive function was screened using the mini-mental state
examination (MMSE) [10] and the Montreal Cognitive
Assessment (MoCA) [11] scales. The total score of
MMSE is 30 points, of which <17 points, <20 points,
and <24 points in illiterate patients, patients with
education level of primary school, and patients with
education level of secondary school or above, respect-
ively, are considered as cognitive disorders. The total
score of MoCA is 30 points, where a score <26 points is
considered as cognitive disorders, using a score +1 to
correct for education level for patients with ≤12 years of
education. MoCA presents a higher sensitivity in screen-
ing mild cognitive disorders, while MMSE is more ef-
fective and convenient for dementia patients with
multiple-domain impairment. In this study, results of
the above two scales were comprehensively considered
since they were only used as quantitative indices of cog-
nitive level variation with the change of non-HDL-C.
Neuropsychological behavior was assessed using the
neuropsychiatric inventory (NPI) [12] to determine the
frequency and severity of behavioral disorders as well as
distress. The NPI included 12 items and a total score of
144 points, where a higher score refers to more severe
psychological and behavioral disorders.
The activities of daily living (ADL) were assessed using
the ADL scale [13], which includes 20 items: 11 items
for basic ADL (BADL) and 9 items of instrumental ADL
(IADL), for a total score of 80 points, where a higher
score refers to a more severe impairment.
The emotional state was assessed using the Hamilton
Rating Scale 21-item HAMD-21 [14], where a score ≥7,
≥17, and ≥24 points refers to mild, moderate, and severe
depression, respectively.
Statistical analysis
Statistical analysis was performed using SPSS 19.0 (IBM,
Armonk, NY, USA). Normally-distributed continuous data
are presented as mean ± standard deviation and were ana-
lyzed using the independent-samples t-test or ANOVA
with the LSD post hoc test, as appropriate. Categorical
data are expressed as frequency and were analyzed using
the chi-square test. Correlations were assessed using the
Pearson correlation test. Logistic regression (stepwise) was
performed to determine the factors independently associ-
ated with higher cognitive impairment. Two-sided
P-values <0.05 were considered statistically significant.
Results
Characteristics of the patients
A total of 725 patients with acute cerebral infarction were
hospitalized at the Department of Neurology of the
Tianjin Huanhu Hospital between October 2010 and
March 2015. They were divided into two groups according
to the non-HDL-C levels: the normal group included 253
patients (192 men and 61 women, aged 54–85 years, mean
age of 63.1 ± 11.9 years) and the high group included 472
patients (336 men and 136 women, aged 52–81 years,
mean age of 62.2 ± 10.8 years). Furthermore, each group
was further divided into three subgroups according to the
OCSP classification: TACI/PACI, POCI, and LACI.
Gender, age, years of education, as well as hyperten-
sion, diabetes, coronary atherosclerotic heart disease,
smoking history, drinking history, family history of de-
mentia, and stroke history were similar between the two
groups (P > 0.05) (Table 1), but BMI in the normal non-
HDL-C group was significantly lower than in the high
non-HDL-C group (P = 0.009) (Table 1). TC, TG, HDL-
C, LDL-C, HCY, fasting blood glucose, HbA1c, and
other indicators were statistically different between the
two groups (P < 0.05) (Table 1), except for hsCRP (P >
0.05). There was no significant difference in OCSP sub-
types between the two groups (P > 0.05).
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Impact of non-HDL-C levels on cognitive impairment
The MMSE and MOCA scores in the high non-HDL-C
group were significantly lower than in the normal non-
HDL-C group (MMSE: P < 0.001; MoCA: P = 0.01). As-
sessments of neuropsychological behavior and emotion
showed that the NPI and HADM-21 scores in the high
non-HDL-C group were higher than in the normal non-
HDL-C group (P < 0.001). Meanwhile, the ADL scale
scores were similar between the two groups (P > 0.05)
(Table 2).
Association of non-HDL-C levels and neurological scores
The high non-HDL-C group was further divided into
the higher than normal non-HDL-C (208 cases), crit-
ical high non-HDL-C (183 cases), and very high non-
HDL-C (81 cases). The NIHSS was significantly
higher in patients with critical high non-HDL-C levels
compared with patients with higher than normal
levels (P < 0.05)(Table 3).
Correlations of non-HDL-C level with various indices
among patients with high non-HDL-C levels
Pearson correlation analyses revealed that MMSE (weak
correlation, r = -0.237, P < 0.001) and MoCA (weak cor-
relation, r = −0.194, P < 0.001) scores were negatively
correlated with non-HDL-C level in patients with acute
Table 1 Socio-demographic and clinical characteristics of the patients
Variables Normal non-HDL-C (n = 253) High non-HDL-C (n = 472) P
Gender, n (%)
M 192 (75.9) 336 (71.2) 0.175
F 61 (24.1) 136 (28.8)
Age (years) 63.1 ± 11.9 62.2 ± 10.8 0.289
BMI (kg/m2) 24.6 ± 3.4 25.3 ± 3.3 0.009
Years of education (years) 9.2 ± 4.3 9.1 ± 3.9 0.788
Hypertension, n (%) 167 (66.0) 317 (67.2) 0.753
Diabetes, n (%) 58 (22.9) 101 (21.4) 0.636
Coronary atherosclerotic heart disease, n (%) 43 (17.0) 88 (18.6) 0.583
Smoking history, n (%) 90 (35.6) 168 (35.6) 0.996
Drinking history, n (%) 67 (26.5) 122 (25.9) 0.853
Family history of dementia, n (%) 10 (4.0) 19 (4.0) 0.962
Stroke history, n (%) 94 (37.2) 151 (32.0) 0.161
Non-HDL-C (mmol/l) 2.77 ± 0.46 4.40 ± 0.86 <0.001
TC (mmol/l) 3.86 ± 0.52 5.54 ± 0.88 <0.001
TG (mmol/l) 1.27 ± 0.56 1.95 ± 0.31 <0.001
HDL-C (mmol/l) 1.08 ± 0.26 1.13 ± 0.25 0.027
LDL-C (mmol/l) 2.16 ± 0.46 3.39 ± 0.80 <0.001
HCY (mmol/l) 14.28 ± 2.01 16.02 ± 3.80 0.044
hsCRP (mg/l) 4.35 ± 0.78 4.47 ± 1.97 0.895
Fasting glucose (mmol/l) 6.05 ± 2.06 6.44 ± 2.66 0.041
HbA1c (%) 6.52 ± 1.17 6.80 ± 1.32 0.013
TACI/PACI, n (%) 167 (66.0) 309 (65.5) 0.264
POCI, n (%) 67 (26.5) 111 (23.5)
LACI, n (%) 19 (7.5) 52 (11.0)
BMI body mass index, non-HDL-C non-high-density lipoprotein cholesterol, TC total cholesterol, TG triglycerides, HDL-C high-density lipoprotein cholesterol, LDL-C
low-density lipoprotein cholesterol, HCY homocysteine, hsCRP high-sensitivity C-reactive protein, HbA1c glycated hemoglobin, TACI total anterior circulation
infarction, PACI partial anterior circulation infarction, POCI posterior circulation infarction, LACI lacunar circulation infarction







MMSE 26.0 ± 4.6 23.1 ± 4.9 <0.001
MoCA 22.2 ± 5.3 20.4 ± 6.4 0.010
NPI 3.3 ± 1.5 6.2 ± 1.2 <0.001
HADM-21 4.5 ± 1.9 6.0 ± 2.2 <0.001
ADL 25.7 ± 8.0 28.2 ± 4.1 0.230
MMSE mini-mental state examination, MoCA Montreal Cognitive Assessment,
NPI Neuropsychiatric Inventory, ADL Activity of Daily Living Scale, HADM-21
Hamilton depression rating scale 21-item
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ischemic stroke. In order to correct the impacts of
gender, age, education level, disease history, and other
confounding factors, we further performed partial cor-
relation analyses, which showed that MMSE (moder-
ate correlation, r = −0.526, P < 0.001) and MoCA
(weak correlation, r = −0.216, P < 0.001) scores were
negatively correlated with non-HDL-C levels, while
NPI scores (weak correlation, r = 0.301, P < 0.001)
were positively correlated with non-HDL-C levels
(Table 4).
Effects of stroke site on cognitive function
Assessment of cognitive function showed that MMSE
and MoCA scores were significantly different among dif-
ferent subtypes of cerebral infarction in the two groups
(P < 0.05), of which the score was the lowest in the
TACI/PACI group, followed by the POCI and LACI
groups. In addition, among different cerebral infarction
subtypes, the MMSE and MoCA scores were signifi-
cantly lower in the high level group compared with the
normal level group (P < 0.001) (Table 5).
Risk analysis of non-HDL-C levels to cognitive impairment
after ischemic stroke
Univariable analyses revealed that non-HDL-C levels,
education level, age, history of diabetes, history of stroke,
family history of dementia, HAMD score, and HCY level
(P < 0.05) were associated with cognitive disorders after
acute ischemic stroke (Table 6). These factors were in-
cluded in the multivariable analysis and the results
showed that high non-HDL-C levels, history of stroke,
low education level, age, HAMD score, and HCY levels
were independently associated with cognitive disorders
after ischemic stroke (all P < 0.05).
Discussion
Non-HDL-C could be a good predictor of vascular dis-
ease outcomes. Therefore, this study aimed to evaluate
the association between serum non-HDL-C and cogni-
tive impairment in patients with acute ischemic stroke.
Results showed that compared with normal non-HDL-C,
patients with high non-HDL-C showed lower MMSE
and MoCA scores, higher NPI and HADM-21 scores,
and higher HCY, fasting blood glucose, and HbA1c
levels. MMSE, MoCA, and NPI scores were correlated
with non-HDL-C levels. High non-HDL-C levels were
an independent risk factor of cognitive disorders after
acute ischemic stroke.
Non-HDL-C was initially used to predict the risk of
cardiovascular diseases and is a strong predictor for all-
cause mortality and cardiovascular disease mortality, and
is significantly superior to LDL-C levels [15]. The Bypass
Angioplasty Revascularization Investigation (BARI) study
assessed the efficacy of secondary prevention in 1514 pa-
tients with multiple coronary diseases, and their 5-year
follow-up revealed that non-HDL-C levels were an inde-
pendent predictor for non-fetal myocardial infarction,
while LDL-C levels failed to have significant predictive















NIHSS 4.0 ± 1.3 3.6 ± 1.1a 4.8 ± 1.8 0.043
NPI 3.9 ± 1.2 4.1 ± 1.2 4.9 ± 1.5ab 0.021
BI 84.1 ± 14.6 84.8 ± 14.4 82.9 ± 16.1 0.217
MMSE 24.9 ± 4.6 24.6 ± 5.1 22.6 ± 6.0ab <0.001
MoCA 20.5 ± 5.0 20.6 ± 5.9 18.3 ± 4.3ab 0.002
ADL 26.3 ± 8.2 26.5 ± 8.4 29.2 ± 10.3 0.450
HAMD 4.8 ± 1.3 4.7 ± 1.0 4.2 ± 2.7 0.634
NIHSS NIH stroke score, MMSE mini-mental state examination, MoCA Montreal
Cognitive Assessment, NPI, Neuropsychiatric Inventory, ADL Activity of Daily
Living Scalem, HADM-21 Hamilton depression rating scale 21-item
aANOVA and LSD post hoc test: P < 0.05 vs. the higher than normal
non-HDL-C group
bANOVA and LSD post hoc test: P < 0.05 vs. the critical high non-HDL-C group
Table 4 Correlation of non-HDL-C levels with neurological scores
Items Pearson correlation analysis Partial correlation analysis
r P r P
MMSE −0.237 <0.001 −0.526 <0.001
NPI 0.059 0.2 0.301 <0.001
MoCA −0.194 <0.001 −0.216 <0.001
HAMD-21 0.028 0.494 0.046 0.316
ADL 0.036 0.388 0.047 0.311
The partial correlation analysis is corrected for the impact of gender, age,
education level, and disease history
MMSE mini-mental state examination, MoCA Montreal Cognitive Assessment,
NPI Neuropsychiatric Inventory, ADL Activity of Daily Living Scale, HADM-21
Hamilton depression rating scale 21-item
Table 5 Comparison of MMSE and MoCA scores of patients
with different cerebral infarctions between the two groups
Normal level (n = 253) High level (n = 472) P
MMSE
TACI/PACI 28.49 ± 1.19 21.94 ± 5.13 <0.001
POCI 29.01 ± 0.83 22.47 ± 4.22 <0.001
LACI 29.50 ± 0.51 23.98 ± 4.04 <0.001
P <0.001 0.019
MoCA
TACI/PACI 25.10 ± 2.97 17.29 ± 6.50 <0.001
POCI 26.05 ± 2.68 17.95 ± 5.68 <0.001
LACI 27.35 ± 1.93 19.62 ± 5.72 <0.001
P 0.003 0.045
MMSE mini-mental state examination, MoCA Montreal Cognitive Assessment,
TACI/PACI total/partial anterior circulation infarction, POCI posterior circulation
infarction, LACI lacunar circulation infarction
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effect on the primary endpoint or mortality [16]. In an-
other clinical longitudinal study with a follow-up >19 years
in 2406 men and 2058 women, the risk of coronary dis-
ease in men with non-HDL-C levels >220 mg/dl was 2.14
times that of men with non-HDL-C levels <160 mg/dl,
while that in people with LDL-C levels >190 mg/dl was
1.77 times that of people with LDL-C levels <130 mg/dl
[15]. Recent studies proposed that serum non-HDL-C
levels were closely associated with cerebral vascular dis-
eases. Indeed, Wu et al. [17, 18] conducted a follow-up
study of 95,916 18-98 year-old patients without stroke or
myocardial infarction in Tangshan (Hebei, China) and
found that serum non-HDL-C levels were an independent
risk factor of ischemic stroke, and that high serum
non-HDL-C levels were associated with an increase of
>50 % of the risk of ischemic stroke in the healthy popula-
tion, which was better than the association between LDL-
C and the same risk. In their study, 13.0 % of the patients
had asymptomatic intracranial arterial stenosis (ICAS)
[17, 18]. In addition, they found that the elevation extent
of serum non-HDL-C levels was positively correlated with
ICAS incidence, and was an independent risk factor for it
(OR = 1.15) [19]. Patients with mild cognitive impairment
(MCI) caused by intracranial stenosis are prone to
deteriorate and progress to dementia, and its mechanism
might be because atherosclerosis cause vascular distortion
and enwinding, but also might induce mechanical occlu-
sion of intracranial vessels. In addition, an important
Table 6 Univariable and multivariable analyses of factors associated with cognitive disorders after acute ischemic stroke
Univariable Multivariable
Variables P OR 95 % CI P OR 95 % CI
Gender, male 0.239 0.729 0.431–1.234
Age 0.001 1.043 1.018–1.068 0.001 1.039 1.016–1.064
BMI 0.623 0.982 0.913–1.056
Years of education <0.001 0.817 0.772–0.866 <0.001 0.808 0.757–0.861
Hypertension 0.324 1.207 0.831–1.755
Diabetes <0.001 1.276 1.175–1.385 0.341 1.400 0.700–2.797
Coronary heart disease 0.388 1.380 0.664–2.870
History of smoking 0.367 1.226 0.788–1.907
History of drinking 0.524 1.221 0.661–2.254
Family history of dementia 0.001 1.219 1.082–1.374 0.055 0.242 0.057–1.031
History of stroke 0.021 1.742 1.087–2.791 0.025 1.723 1.071–2.771
High TC 0.629 0.791 0.306–2.044
High TG 0.674 1.078 0.760–1.529
Low HDL-C 0.088 0.650 0.396–1.066
High LDL-C 0.900 1.025 0.694–1.514
High Non-HDL-C 0.034 3.115 1.088–8.917 <0.001 3.115 1.088–8.917
Normal level 0.170 1.691 0.799–3.579 0.088 1.691 0.799–3.579
Higher than normal 0.046 2.710 1.017–7.221 0.052 2.710 1.017–7.221
Critical high level 0.026 5.877 1.231–28.065 0.040 5.877 1.231–28.065
Very high level 0.013 7.006 1.502–32.675 0.932 7.006 1.502–32.675
High Hcy <0.001 1.060 1.032–1.088 <0.001 1.057 1.031–1.084
hsCRP 0.515 0.990 0.960–1.021
Fasting hyperglycemia [n (%)] 0.285 1.084 0.935–1.256
High HbA1c 0.960 1.002 0.939–1.068
NPI 0.218 1.039 0.978–1.104
HAMD-21 0.001 1.224 1.089–1.375 0.001 1.284 1.177–1.401
ADL 0.141 1.012 0.996–1.029
BMI body mass index, Non-HDL-C non-high-density lipoprotein cholesterol, TC total cholesterol, TG triglycerides, HDL-C high-density lipoprotein cholesterol, LDL-C
low-density lipoprotein cholesterol, HCY homocysteine, hsCRP serum high-sensitivity C-reactive protein, HbA1c glycated hemoglobin, MMSE mini-mental state
examination, MoCA Montreal Cognitive Assessment, NPI Neuropsychiatric Inventory, ADL Activity of Daily Living Scale, HADM-21 Hamilton depression rating
scale 21-item
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atherosclerotic stenosis might indicate systemic athero-
sclerosis and extensive microvascular diseases, damage of
microcirculation, increased resistance of small vessels and
decreased vascular reactivity, ultimately leading to cerebral
hypoperfusion. The cumulative effect of these inter-
dependent hemodynamic disorders might play a key role
in accelerating the onset and progression of cognitive dis-
orders [20]. Some studies also found that serum non-
HDL-C levels were significantly increased in patients with
MCI compared with people with normal cognitive func-
tion, and the cognitive score was negatively correlated
with the non-HDL-C levels (r = −0.761) [21]. This cross-
sectional analysis first discovered that the non-HDL-C
levels in 65.1 % of the patients with acute ischemic stroke
was significantly higher than the normal value, and that it
was positively correlated with the prevalence and damage
extent of cognitive impairment after acute ischemic
stroke. Thus, serum non-HDL-C level might have high
value in predicting the disease since it was an independent
risk factor of vascular cognitive impairment.
In this study, various neurological scores were assessed
in patients with different levels of serum non-HDL-C,
and patients with serum non-HDL-C levels higher than
the normal value tended to present significant cognitive
impairment and were accompanied by apparent mental
behavior and emotion disorders, significantly affecting
their ability and quality of life. Multivariable regression
analyses found that the risk of cognitive disorders after
acute ischemic stroke was increased significantly when
non-HDL-C levels were higher than normal. Therefore,
serum non-HDL-C levels were an independent risk fac-
tor of cognitive disorders after cerebral stroke. A recent
study showed that high LDL-C levels and low HDL-C
levels were associated with β-amyloid-associated cogni-
tive impairment, suggesting that cholesterol levels play
an important role in cognitive function [22]. Additional
studies are necessary to assess their precise role in neu-
rodegenerative diseases and cognitive impairment.
Damage from non-HDL-C to cognitive impairment
after stroke could be associated with its strong associ-
ation with the development of atherosclerosis. First,
non-HDL-C particles include all potentially athero-
genic lipoproteins [23–25]. Secondly, a high concen-
tration of TG and VLDL-C in non-HDL-C reflects an
increase of the liver’s potential to generate lipopro-
teins causing atherosclerosis, leading to decreased
interaction of these lipoproteins with liver receptors
and reduced clearance. Therefore, these lipoproteins
tend to be retained in blood circulation for a longer
time, thereby promoting atherosclerosis. Finally, some
lipoprotein remnants containing abundant TG may
enter the arterial walls, leading to occurrence and de-
velopment of atherosclerosis [7, 26]. Therefore, com-
pared with LDL-C, serum non-HDL-C plays a higher
effect in inducing atherosclerosis and LDL-C alone
tend to neglect the promoting effect of other lipopro-
teins on ischemic stroke.
This study also showed that cognitive function scores
were associated with the type of cerebral stroke in pa-
tients with high serum non-HDL-C levels and cerebral
infarction. The score was the lowest in patients with
CACI/PACI and the highest in patients with LACI, indi-
cating an association with injury to specific brain
regions. CACI/PACI mainly involve the middle cerebral
artery territory; a large lesion in the dominant hemi-
sphere or bilateral hemispheric lesions can obviously in-
volve the temporal lobe, insula, corpus callosum,
hippocampus, and other parts that are closely associated
with cognitive and memory functions, whereas the LACI
normally has a smaller effect on the cognitive function
unless the above specific locations are involved [27].
Cross-sectional analyses revealed that elevation of
serum non-HDL-C levels were accompanied by elevated
blood glucose and serum HCY levels. Previous studies
found that patients with type 2 diabetes often suffered
from dyslipidemia, especially patients with uncontrolled
blood glucose. Abnormal lipid metabolism is mainly as-
sociated with diabetic vascular diseases, where specific
lipid modulation or low-fat diet is likely to prevent or
delay the progression of diabetic vascular diseases, sug-
gesting that lipid metabolism disorders and diabetes
have common pathophysiology for cognitive disorders
after cerebral stroke [28]. In addition, patients with dia-
betes often also suffer from impaired renal function, and
it has been shown that patients with decreased flomeru-
lar filtration rate also had greater levels of cognitive im-
pairment [29]. Nevertheless, since the relationships of all
these factors are complex, additional studies are neces-
sary to assess comprehensively all these factors together.
In this study, regression analyses showed that the risk
of cognitive disorders in patients with high serum HCY
level was 1.057 times that of patients with a low level.
which might be associated with high HCY-induced
neurotoxicity [30]. These results agree with a recent
study that showed that patients with vascular cognitive
impairment have high HCY levels [31]. Accordingly, de-
creasing HCY levels seems to be associated with better
cognitive outcomes in patients with Alzheimer’s disease
[32], suggesting that lowering HCY levels after an ische-
mic stroke could improve the outcomes, but additional
studies are necessary to address this issue.
In addition, a low education level, age, high HAMD
score, history of cerebral stroke, and family history of
dementia were independent risk factors of cognitive dis-
orders after ischemic stroke. These results are consistent
with a previous study that showed that lower education,
history of diabetes, high HAMD scores, high hsCRP
levels, and high HbA1c levels were associated with
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cognitive impairment after acute ischemic stroke [33].
However, these results were all obtained in relatively
small studies and need to be confirmed in larger trials.
This study is not without limitations. This was a
single-center retrospective cohort study with a small
sample size and limited follow-up duration. Only a lim-
ited number of variables could be assessed because of
the retrospective nature of the study. Additional studies
are necessary to confirm these findings.
Conclusions
In conclusion, high serum non-HDL-C levels might sig-
nificantly increase the risk of cognitive disorders after
acute cerebral stroke. As an inexpensive and easily mea-
sured biomarker, non-HDL-C screening could be under-
taken for primary prevention of cognitive disorders after
acute cerebral stroke in Chinese adults, but also provide
a new direction for investigating treatment for cognitive
disorders after acute cerebral stroke.
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